Pharmacy Week in Review: December 18, 2015

Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.

Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.

Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.

In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.

Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.

Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.

AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.

Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.